Latest Commercialization News

Hummgroup Limited reported a robust FY25 with cash profit soaring to $52.9 million, a significant reduction in costs, and a maintained historically low credit loss ratio. The group also completed a full repayment of its Perpetual Notes, signaling improved capital efficiency.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

Core Lithium Ltd has launched a non-underwritten equity raising to secure approximately A$60 million, aiming to advance its Finniss Lithium Project to a final investment decision. The capital raise includes a two-tranche placement and a share purchase plan, supporting operational readiness and strategic funding efforts.

Solvar Limited’s FY25 results highlight solid loan book growth in Australia, the strategic launch of Bennji commercial finance, and a significant 40% increase in dividends, underpinning confidence in future earnings.

Orcoda Limited faced a challenging FY25 due to delayed projects from a key customer but is poised for recovery with new contracts and growth in recurring revenue. The company’s strategic diversification and AI-powered solutions underpin a confident outlook for FY26.

Nickel Industries reported a robust 81% rise in half-year profit to US$25.5 million, while advancing the Excelsior Nickel Cobalt project towards commissioning. The company also declared a final dividend and highlighted sustainability achievements.

Solvar Limited reported a robust FY25 with a 17.4% increase in normalised NPAT and launched Bennji, a new commercial lending brand targeting small businesses.

Clever Culture Systems Ltd has reported a remarkable 288% jump in revenue to $6.63 million for the year ended June 2025, turning around from a loss to a net profit of $1.68 million, buoyed by strong product sales and government support.

De.mem Limited has reported a record half-year performance for 2025, with revenue up 20% and its first positive adjusted EBITDA, driven by strong recurring revenues and strategic acquisitions.

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.